Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections

被引：36
|
作者：
Ferrara, Giovanni [2 ,3 ]
Zumla, Alimuddin [4 ]
Maeurer, Markus [1 ,2 ]
机构：
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, SE-17182 Stockholm, Sweden
[2] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat CAST, Stockholm, Sweden
[3] Univ Perugia, Sect Resp Dis, S Maria Hosp, Terni, Italy
[4] UCL, Sch Med, Div Infect & Immun, London W1N 8AA, England
来源：
AMERICAN JOURNAL OF MEDICINE | 2012年 / 125卷 / 10期
基金：
英国医学研究理事会;
关键词：
Clinical use; Difficult-to-treat infection; Immune response; Intravenous immunoglobulin; Tuberculosis; RED-CELL APLASIA; BACTERIAL-INFECTIONS; REPLACEMENT THERAPY; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; GAMMA AUTOANTIBODY; DENDRITIC CELLS; HIV-INFECTION; LUNG-DISEASE; ANTIBODIES;
D O I：
10.1016/j.amjmed.2012.01.023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Traditionally, intravenous immunoglobulin (IVIg) has been used as replacement therapy for patients with primary or secondary immunoglobulin deficiencies. Increasingly, IVIg is being used (in doses higher than for replacement therapy) in certain bacterial or viral infectious diseases. A variety of modes of action have been attributed to the beneficial effects of IVIg, including its interaction with T-cell function, antigen-presenting cell maturation/presentation, combined with a general "tune down" effect on inflammatory reactions. More often, IVIg is being evaluated in clinical trials for the treatment of refractory and difficult-to-treat chronic infections. The evidence, molecular mechanisms, and rationale for the use of adjunct IVIg therapy in infectious diseases are reviewed, and its potential use in the adjunct treatment of difficult-to-treat drug-resistant tuberculosis discussed. (C) 2012 Elsevier Inc. All rights reserved. The American Journal of Medicine (2012) 125, 1036.e1-1036.e8
引用
收藏
页数：8
相关论文
共 50 条
  • [1] USE OF INTRAVENOUS CIPROFLOXACIN IN DIFFICULT-TO-TREAT INFECTIONS
    GIAMARELLOU, H
    GALANAKIS, N
    [J]. AMERICAN JOURNAL OF MEDICINE, 1987, 82 (4A): : 346 - 351
  • [2] DIFFICULT-TO-TREAT INFECTIONS
    DEMARIE, S
    [J]. INTENSIVE CARE MEDICINE, 1990, 16 : S239 - S242
  • [3] CHEMOTHERAPEUTIC POSSIBILITIES IN DIFFICULT-TO-TREAT INFECTIONS
    WILLIAMS, JD
    [J]. INFECTION, 1980, 8 (06) : 309 - 313
  • [4] USE OF CEFOXITIN SODIUM IN DIFFICULT-TO-TREAT INFECTIONS
    NAIR, SR
    CHERUBIN, CE
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1978, 4 : 167 - 178
  • [5] Personalized bacteriophage therapy for difficult-to-treat infections
    Iredell, Jonathan
    Sinclair, Holly
    Khatami, Ameneh
    [J]. NATURE MICROBIOLOGY, 2024, : 1401 - 1402
  • [6] Infections Mimicking Difficult-to-Treat Systemic Lupus Erythematosus
    Shukla, Anuj
    [J]. INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (01) : 93 - 98
  • [7] Reference guide for difficult-to-treat fungal infections - Preface
    Ghannoum, MA
    [J]. JOURNAL OF CHEMOTHERAPY, 2003, 15 : 3 - 3
  • [8] Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections
    Abdallah, Tasneem A. K.
    Elajez, Reem
    Ibrahim, Tawheeda B.
    Alimam, Abeir B.
    Omrani, Ali S.
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (11) : 1620 - 1622
  • [9] Difficult-to-Treat depression
    Kupfer, DJ
    Charney, DS
    [J]. BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 633 - 634
  • [10] Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin
    Valour, Florent
    Dutronc, Herve
    Dinh, Aurelien
    Cazorla, Celine
    Pavese, Patricia
    Lesens, Olivier
    Uckay, Ilker
    Chidiac, Christian
    Ferry, Tristan
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 41 (02) : 197 - 199
12345